1.Electroacupuncture at acupoints of yangming meridians for sarcopenia: a randomized controlled trial.
Su-Fan MA ; Wan-Yong LV ; Qian-Yang ZHU ; Hui-Jia LI ; Jing-Jing LI ; Qian SHI ; Xin-Ru LU ; Han-Yue YAO ; Cai-Rong ZHANG
Chinese Acupuncture & Moxibustion 2023;43(10):1114-1117
OBJECTIVE:
To observe the clinical effect of electroacupuncture at acupoints of yangming meridians for sarcopenia.
METHODS:
A total of 60 patients with sarcopenia were randomized into an observation group and a control group, 30 cases in each group. In the control group, conventional nutrition intervention for sarcopenia was adopted. In the observation group, on the basis of the treatment in the control group, acupuncture was applied at bilateral Binao (LI 14), Quchi (LI 11), Zusanli (ST 36), Yanglingquan (GB 34), etc.,ipsilateral Quchi (LI 11) and Zusanli (ST 36) were connected to electroacupuncture, with discontinuous wave, 2 Hz in frequency, 1-10 mA in intensity, 2 times a week, with a interval of 3 days. A total of 12-week treatment was required in the two groups. Before and after treatment, the appendicular skeletal muscle mass index (ASMI), grip strength, 6 m-walking time, body fat percentage and body moisture percentage were observed in the two groups.
RESULTS:
Compared with those before treatment, after treatment, ASMI and grip strength were increased while 6 m-walking time was shortened in the two groups (P<0.05); body fat percentage was decreased while body moisture percentage was increased in the observation group (P<0.05). After treatment, in the observation group, ASMI, grip strength and body moisture percentage were increased (P<0.05), 6 m-walking time was shortened and body fat percentage was decreased (P<0.05) compared with those in the control group.
CONCLUSION
Electroacupuncture at acupoints of yangming meridians can effectively improve the skeletal muscle mass, muscle function, body fat percentage and body moisture percentage in patients with sarcopenia, and make the distribution of muscle and fat more reasonable.
Humans
;
Meridians
;
Acupuncture Points
;
Electroacupuncture
;
Sarcopenia/therapy*
;
Acupuncture Therapy
2.Regulatory roles of microRNAs in sarcopenia and exercise intervention.
Ji-Ling LIANG ; Jin-Feng XIE ; Cen-Yi WANG ; Ning CHEN
Acta Physiologica Sinica 2020;72(5):667-676
Sarcopenia is an age-related degenerative disease, in which skeletal muscle mass and function are reduced during aging process. Physical intervention is one of the most effective strategies available for the treatment of sarcopenia. Studies have shown that microRNAs (miRNAs), as important regulators of gene expression, play an important role in maintaining the homeostasis of senescent skeletal muscle cells by regulating skeletal muscle cell development (proliferation and differentiation), mitochondrial biogenesis, protein synthesis and degradation, inflammatory response and metabolic pathways. Furthermore, exercise can combat age-related changes in muscle mass, composition and function, which is associated with the changes in the expression and biological functions of miRNAs in skeletal muscle cells. In this article, we systematically review the regulatory mechanisms of miRNAs in skeletal muscle aging, and discuss the regulatory roles and molecular targets of exercise-mediated miRNAs in muscular atrophy during aging process, which may provide novel insights into the prevention and treatment of sarcopenia.
Aging/genetics*
;
Exercise Therapy
;
Humans
;
MicroRNAs/genetics*
;
Muscle, Skeletal
;
Sarcopenia/therapy*
3.Clinical Characteristics of Sarcopenia and Cachexia.
Journal of Clinical Nutrition 2017;9(1):2-6
Sarcopenia, which is defined as a decrease in skeletal muscle mass and strength with aging, is an important risk factor in clinical medicine that is associated with mortality, and poor surgical and nonsurgical outcomes. Sarcopenia is now recognized as a multifactorial geriatric syndrome. Cachexia is defined as a metabolic syndrome with inflammation as the key feature, so cachexia can be an underlying condition of sarcopenia. Recently, cachexia has been defined as a complex metabolic syndrome associated with an underlying illness and characterized by the loss of muscle mass with or without a loss of fat mass. These two conditions overlap but are not the same. In clinical practice, many factors related to sarcopenia (decreased food intake, inactivity, and decreased hormones) are reported frequently in patients with cachexia. On the contrary, systemic inflammation, the core feature of cachexia, can also be present in apparently healthy older sarcopenic patients. This suggests that new therapeutic approaches, alone or in combination, may be appropriate in both conditions.
Aging
;
Cachexia*
;
Clinical Medicine
;
Eating
;
Humans
;
Inflammation
;
Mortality
;
Muscle, Skeletal
;
Nutrition Therapy
;
Risk Factors
;
Sarcopenia*
4.Integrative Approach to Elderly Frailty.
Byoung Jin PARK ; Yong Jae LEE
Korean Journal of Family Medicine 2010;31(10):747-754
Elderly frailty has been recognized as a distinct clinical syndrome with a physiologic basis. It reflects a decreased functional reserve and consequent reduction in resilience to any stressors. It is important to understand that frailty process could be a transitional state with dynamic properties: normal aging-->pre-frail-->frailty-->complication status. Hence, frailty could be preventable and its progression may be delayed. Furthermore, there is the potential reversibility of many of its features. The earlier stages of frailty might not be clinically apparent, but later stages manifest as significant deficits accumulate. The major phenotype of frailty includes weight loss, sarcopenia, relative inactivity, decreased balance and mobility, decreased cognitive function, and impaired nutritional status. Therefore, frail patients could be implicated by decreased performance status and have a significantly increased risk of cardiovascular diseases, cancer, falls and mortality. Regular exercise, essential amino acid and vitamin D are recommendable to prevent and treat elderly frailty, but hormone replacement therapy does not have consistent evidence yet. In upcoming (super) aging society, the importance of elderly frailty would be more noticed and multidisplinary approach should be actively performed.
Aged
;
Aging
;
Cardiovascular Diseases
;
Hormone Replacement Therapy
;
Humans
;
Integrative Medicine
;
Nutritional Status
;
Phenotype
;
Sarcopenia
;
Vitamin D
;
Weight Loss
5.Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer.
Carolina PALMELA ; Sónia VELHO ; Lisa AGOSTINHO ; Francisco BRANCO ; Marta SANTOS ; Maria Pia Costa SANTOS ; Maria Helena OLIVEIRA ; João STRECHT ; Rui MAIO ; Marília CRAVO ; Vickie E BARACOS
Journal of Gastric Cancer 2017;17(1):74-87
PURPOSE: Neoadjuvant chemotherapy has been shown to improve survival in locally advanced gastric cancer, but it is associated with significant toxicity. Sarcopenia and sarcopenic obesity have been studied in several types of cancers and have been reported to be associated with higher chemotherapy toxicity and morbi-mortality. The aim of this study was to assess the prevalence of sarcopenia/sarcopenic obesity in patients with gastric cancer, as well as its association with chemotherapy toxicity and long-term outcomes. MATERIALS AND METHODS: A retrospective analysis was performed using an academic cancer center patient cohort diagnosed with locally advanced gastric cancer between January 2012 and December 2014 and treated with neoadjuvant chemotherapy. We analyzed body composition (skeletal muscle and visceral fat index) in axial computed tomography images. RESULTS: A total of 48 patients met the inclusion criteria. The mean age was 68±10 years, and 33 patients (69%) were men. Dose-limiting toxicity was observed in 22 patients (46%), and treatment was terminated early owing to toxicity in 17 patients (35%). Median follow-up was 17 months. Sarcopenia and sarcopenic obesity were found at diagnosis in 23% and 10% of patients, respectively. We observed an association between termination of chemotherapy and both sarcopenia (P=0.069) and sarcopenic obesity (P=0.004). On multivariate analysis, the odds of treatment termination were higher in patients with sarcopenia (odds ratio 4.23; P=0.050). Patients with sarcopenic obesity showed lower overall survival (median survival of 6 months [95% confidence interval 3.9–8.5] vs. 25 months [95% confidence interval 20.2–38.2]; log-rank test P=0.000). CONCLUSIONS: Sarcopenia and sarcopenic obesity were associated with early termination of neoadjuvant chemotherapy in patients with gastric cancer; additionally, sarcopenic obesity was associated with poor survival.
Body Composition*
;
Cohort Studies
;
Diagnosis
;
Drug Therapy*
;
Follow-Up Studies
;
Humans
;
Intra-Abdominal Fat
;
Male
;
Multivariate Analysis
;
Neoadjuvant Therapy
;
Obesity
;
Prevalence
;
Prognosis
;
Retrospective Studies
;
Sarcopenia
;
Stomach Neoplasms*
6.Effects of Androgen on the Cardiovascular System in the Aging Male.
Jin Wook KIM ; Je Jong KIM ; Du Geon MOON
Korean Journal of Andrology 2011;29(1):10-20
Testosterone decrease in men with age has become well established. As such, several modes of testosterone replacement therapy have become available, primarily for supplementation to alleviate the effects of age associated hypogonadism, as manifested by frailty, sarcopenia, poor muscle quality, decreased libido and erectile functions. Recent investigations have found significant association between hypogonadism and cardiovascular disease, type 2 diabetes, obesity and dyslipidemia. The association is more clearly presented in patients receiving androgen deprivation therapy for prostate cancer. Furthermore, testosterone supplementation restores arterial vasoreactivity, reduces proinflammatory cytokines, total cholesterol, and triglyceride levels, and improves endothelial function and insulin sensitivity. Future long term trials should be performed to identify persistent benefits and safety of this treatment.
Aging
;
Androgens
;
Cardiovascular Diseases
;
Cardiovascular System
;
Cholesterol
;
Cytokines
;
Dyslipidemias
;
Hormone Replacement Therapy
;
Humans
;
Hypogonadism
;
Insulin Resistance
;
Libido
;
Male
;
Muscles
;
Obesity
;
Prostatic Neoplasms
;
Sarcopenia
;
Testosterone
7.Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
Inkeun PARK ; Seung Joon CHOI ; Young Saing KIM ; Hee Kyung AHN ; Junshik HONG ; Sun Jin SYM ; Jinny PARK ; Eun Kyung CHO ; Jae Hoon LEE ; Yong Ju SHIN ; Dong Bok SHIN
Cancer Research and Treatment 2016;48(4):1264-1273
PURPOSE: The aim of this study was to verify prognostic factors including sarcopenia in patients with recurrent or metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. MATERIALS AND METHODS: Medical records and computed tomography scan of consecutive patients treated with palliative gemcitabine-based chemotherapy from 2008 to 2014 were reviewed. The lumbar skeletal muscle index at third lumbar spine level was computed, and together with clinicolaboratory factors, univariate and multivariable analyses for overall survival (OS) were performed. RESULTS: A total of 88 patients were found. Median age was 65 years, and male patients were predominant (67.0%). Most patients had initially metastatic disease (72.7%), and gemcitabine monotherapy was administered in 29 patients (33.0%) while gemcitabine plus erlotinib was administered in 59 patients (67.0%). Seventy-six patients (86.3%) had sarcopenia. With a median follow-up period of 44.3 months (range, 0.6 to 44.3 months), median OS was 5.35 months (95% confidence interval [CI], 4.11 to 6.59). In univariate and multivariable analysis, high carcinoembryonic antigen level (hazard ratio [HR], 4.18; 95% CI, 1.95 to 8.97; p < 0.001), initially metastatic disease (HR, 3.37; 95% CI, 1.55 to 7.32; p=0.002), sarcopenia (HR, 2.97; 95% CI, 1.20 to 7.36; p=0.019), neutrophilia (HR, 2.94; 95% CI, 1.27 to 6.79; p=0.012), and high lactate dehydrogenase level (HR, 1.96; 95% CI, 1.07 to 3.58; p=0.029) were identified as independent prognostic factors for OS. CONCLUSION: Five independent prognostic factors in patients with recurrent or metastatic pancreatic cancer who received gemcitabine-based chemotherapy were identified. These findings may be helpful in prediction of prognosis in clinical practice and can be used as a stratification factor for clinical trials.
Adenocarcinoma*
;
Carcinoembryonic Antigen
;
Drug Therapy*
;
Erlotinib Hydrochloride
;
Follow-Up Studies
;
Humans
;
L-Lactate Dehydrogenase
;
Male
;
Medical Records
;
Muscle, Skeletal
;
Pancreatic Neoplasms
;
Prognosis
;
Sarcopenia
;
Spine
8.Sarcopenia Associated with Chronic Obstructive Pulmonary Disease
Sang Hun KIM ; Myung Jun SHIN ; Yong Beom SHIN ; Ki Uk KIM
Journal of Bone Metabolism 2019;26(2):65-74
Sarcopenia is frequently associated with chronic diseases such as chronic obstructive pulmonary disease (COPD) and cancer. COPD, which is characterized by an irreversible airflow limitation, exacerbates respiratory distress as the disease progresses. The prevalence of sarcopenia in stable COPD was reported to be 15% to 25% in previous foreign studies and 25% in a Korean study. As the amount of activity decreases, muscle mass decreases and eventually oxygen cannot be used effectively, resulting in a vicious cycle of deterioration of exercise capacity. Deconditioning due to decreased activity is a major cause of limb muscle dysfunction in patients with COPD. In these patients, the factors that decrease muscle strength and endurance include chronic inflammation, oxidative stress, inactivity, hypoxemia, hormone abnormality, deficits of nutrients such as protein and vitamin D, and the use of systemic corticosteroid. Therefore, treatment and management should either inhibit this process or should be directed toward supplementing the deficiency, such as with exercise, nutritional support, and medications and supplements. The relationship between sarcopenia and COPD is increasingly being reported, with some overlap in clinical features and treatments. We are fascinated to be able to diagnose 2 diseases through similar physical performance tests and to improve both diseases using the same treatment such as exercise. Therefore, this review summarizes the clinical relevance and integrative management of the 2 diseases.
Anoxia
;
Chronic Disease
;
Exercise Therapy
;
Extremities
;
Humans
;
Inflammation
;
Lung Diseases
;
Muscle Strength
;
Nutritional Support
;
Oxidative Stress
;
Oxygen
;
Prevalence
;
Pulmonary Disease, Chronic Obstructive
;
Rehabilitation
;
Sarcopenia
;
Vitamin D
9.Assessment of lower extremity muscle mass, muscle strength, and exercise therapy in elderly patients with diabetes mellitus.
Takuo NOMURA ; Toshihiro KAWAE ; Hiroaki KATAOKA ; Yukio IKEDA
Environmental Health and Preventive Medicine 2018;23(1):20-20
The increase in the proportion of elderly people in the population is one of the most remarkable sociodemographic phenomena of the twenty-first century. The number of patients with diabetes is also increasing worldwide with this demographic change. Given these facts, consideration of the problems the general elderly population is facing in the management of diabetes is essential. In this review article, we focus on sarcopenia, which is the decrease in lower extremity muscle mass and muscle strength accompanying aging, describe the relationship between sarcopenia and diabetes, and highlight the specific factors through which diabetes contributes to loss of muscle strength. The quantitative methods for evaluating lower extremity muscle strength will also be described. These methods hold the key to assessing the effectiveness of exercise therapy and optimizing the assessment of the degree of autonomy in the activities of daily living. Exercise is one of the basic treatments for type 2 diabetes and may also prevent and improve sarcopenia. This review discusses the aspects common to the two health conditions and elucidates the effectiveness and necessity of exercise as a preventive measure against diabetes among the elderly.
Aged
;
Aged, 80 and over
;
Diabetes Mellitus, Type 2
;
physiopathology
;
prevention & control
;
Exercise Therapy
;
Female
;
Humans
;
Leg
;
physiopathology
;
Male
;
Muscle Strength
;
physiology
;
Muscle, Skeletal
;
physiology
;
Sarcopenia
;
physiopathology
;
prevention & control